October 1989

Idazoxan: A Selective α2-Antagonist and Effective Sustained Antidepressant in Two Bipolar Depressed Patients

Author Affiliations

Section on Clinical Pharmacology National Institute of Mental Health Bethesda, MD 20892

Arch Gen Psychiatry. 1989;46(10):958-959. doi:10.1001/archpsyc.1989.01810100100021

To the Editor.—  We report on the therapeutic and biochemical effects of short- and long-term administration of idazoxan, a selective α2-administration and a putative antidepressant, in three patients with the diagnosis of depression and a history of poor response to standard treatments. The down regulation of central β-receptors in response to increased synaptic norepinephrine (NE) levels has consistently been demonstrated after tricyclic antidepressant1 as well as other effective treatments for depression.2,3 In addition, α2-adrenergic receptors have been shown to down regulate in response to at least some antidepressants.4,5 Furthermore, blockade of α-receptors can accelerate the down regulation of β-receptors by tricyclic antidepressants in rats,6 probably by enhancing intrasynaptic NE through the blockade of prejunctional α2-receptors that normally mediate feedback inhibition of NE release.7 In human studies, however, the addition of yohimbine therapy to patients who had failed to respond

First Page Preview View Large
First page PDF preview
First page PDF preview